Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMA PET/MRI for Prostate Biopsy Guidance
NCT03187990Completed
- Start
- Mar 2017
- Primary completion
- Aug 2021
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Open-label trial of gallium ga-68 gozetotide in prostate cancer (PCa) (2 arms). Primary endpoint: Rate of positive histopathology for [68Ga]PSMA-11 positive lesions at 7 months. Started Mar 2017; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03187990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03187990.